Our Work
Upcoming Events
Want to stay informed about important policy, market access, and health economics issues? Join us for our monthly sessions to learn more!
June
Navigating Market Access with Magnolia
Stay Tuned for More Information!
We would love to have you join our free, monthly educational series, “Navigating Market Access with Magnolia”!
Insights
We offer personalized insights and strategy, and spotlight data in a compelling way to shape policy, communicate value, secure reimbursement, and drive patient access.
-
MFN Policy Executive Order: What It Means for Pricing, Distribution, and Biopharma Strategy
On May 12, 2025, President Trump signed an executive order with the potential to significantly change the U.S. drug pricing and distribution system. Here is what we know about the Administration’s new Most Favored Nation (MFN) policy:
-
Frailty, Real-World Data, and the Access Imperative: A Q&A with Magnolia’s Mike Murphy
At Magnolia Market Access, we see frailty as a key variable in evidence generation and access strategy. Ahead of ISPOR 2025, we sat down with Mike Murphy to discuss Magnolia’s latest research using administrative claims data to evaluate frailty indices.
-
Using Data-Driven Coverage Assessments to Unlock Medicare Part D Formulary Intelligence
Formulary coverage assessments are a critical component of successful market access strategies. As payer policies grow more complex and cost-containment tactics become more aggressive, pharmaceutical manufacturers must stay ahead of how coverage decisions impact product access, prescriber behavior, and ultimately, patient outcomes.
Market Access Briefs
A Blend of Core Concepts and Breaking Headlines
-
What is the Congressional Budget Office (CBO)?
The Congressional Budget Office (CBO) is an independent, nonpartisan agency that serves Congress by providing economic and budgetary analyses of proposed legislation. It estimates the financial impact of proposed bills and assigns them a budget score, which is used by lawmakers to determine how the bill will affect the federal budget over a typical 5-to-10-year…
-
Prescription Drug Affordability Boards (PDABs)
What are PDABs? Prescription Drug Affordability Boards (PDABs) are state-appointed entities empowered to review drug prices, and, in some cases, set upper payment limits (UPLs) in an attempt to lower drug costs for identified populations within the state. The boards typically consist of five to nine members with expertise in healthcare economics, pharmacology, medicine, health…
-
Medicare Part D Changes for 2025
Direct Drug Price Negotiations and Inflation Rebates The Inflation Reduction Act (IRA) made several key changes to Part D. The Centers for Medicare and Medicaid Services (CMS) can now negotiate drug prices for certain high-priced/high-utilization medications. Additionally, drug companies are now required to pay CMS a rebate for Part D and B drugs if prices…